Researchers at Oregon Health & Science University completed a 12-week pilot study showing that time-restricted eating is safe and feasible for patients with early-stage Huntington’s disease, while lowering a key biomarker of nerve cell damage.
For decades, medical researchers have understood the genetic cause of Huntington’s disease, yet approved therapies that actively halt or slow its progressive neurodegeneration remain entirely out of reach. Huntington’s disease is a rare, inherited neurological disease that gradually damages nerve cells responsible for movement, cognitive and emotional regulation. There is currently no therapy that slows the underlying neurodegenerative process; available drugs manage symptoms, chiefly the movement disorder, while the disease continues its course. That grim trajectory focused scientific attention on cellular metabolism, because evidence suggests that mitochondrial dysfunction and altered energy metabolism are central players in the disease process.
Oregon Health & Science University Pilot Trial Protocol and Patient Adherence
Testing fasting in Huntington’s patients carried immediate clinical risks. Because unintended weight loss frequently accompanies the disease as it advances, asking patients to restrict their daily eating schedule seemed counterintuitive to physicians.
To evaluate whether patients could manage the regimen without harmful weight loss, researchers structured a 12-week pilot study involving twenty participants with early-stage disease. The 20 participants selected an eating window that fit their daily routine, typically between late morning and early evening, and followed it for 12 weeks. Researchers encouraged participants to maintain their normal calorie intake and monitored weight and safety throughout the study.
The intervention proved remarkably well-tolerated. Participants avoided unintended weight loss and showed improvements in measures of disease severity; in a blood biomarker linked to nerve cell damage; and in cellular energy production.
Biomarker Shifts and Clinical Score Improvements
Analyses revealed encouraging signals across clinical and biological measures, pointing to improvements in clinical measures, in levels of plasma neurofilament light — a biomarker of ongoing neurodegeneration — and in cellular bioenergetics. Participants in the 12-week pilot study were able to safely follow a form of intermittent fasting known as time-restricted eating—limiting food consumption to a six-to-eight-hour window each day.
What was exciting about this study is that participants were able to maintain their weight while showing signs that the intervention may be positively affecting the disease itself. The findings do not establish time-restricted eating as a treatment, but they mark a step in moving a strategy studied in laboratory animals into the clinic for one of the neurodegenerative conditions.
Translating Preclinical Mouse Models Into Human Clinical Trials
The scientific rationale for testing fasting in Huntington’s disease stretches back more than two decades. In 2003, a team led by Wenzhen Duan reported in the Proceedings of the National Academy of Sciences that dietary restriction normalized glucose metabolism and slowed disease progression in a mouse model of the disorder. That observation seeded a line of research that matured into a review published in Translational Neurodegeneration in 2024, in which R. G. Wells, L. E. Neilson, A. W. McHill and A. L. Hiller synthesized the animal evidence on dietary fasting and time-restricted eating in Huntington’s disease and proposed mechanisms through which periodic metabolic stress might protect the neurons that die in patients.
Prior research in animal models suggests that intermittent fasting can activate cellular pathways that help protect brain cells. Yet researchers were unsure whether the approach would be safe for people with Huntington’s disease because unintended weight loss is already a concern. The approach appeared well positioned for further investigation based on these initial pilot findings.